Development Pipeline
Key clinical studies our Group is conducting in respect of the indications for which we are pursuing approvals in Japan, USA and Europe. If multiple studies are underway in the same region or in relation to the same indication, only the study in the most advanced stage of development is shown.
As of May 13, 2025
Psychiatry & Neurology
Brand name/Generic name/Product code | Proposed indication | Region | Development stage | |
---|---|---|---|---|
Small molecule | ||||
LATUDA®/lurasidone hydrochloride | (New usage: pediatric) Schizophrenia | Japan | Phase 3 | |
DSP-0038 | Alzheimer’s disease psychosis | U.S. | Phase 1 | |
DSP-0187 | Narcolepsy | Japan | Phase 1 | |
DSP-3456 | Treatment resistant depression | U.S. | Phase 1 | |
DSP-0378 | Progressive Myoclonic Epilepsy and Developmental Epileptic Encephalopathy | Japan | Phase 1 | |
DSP-2342 | To be determined | U.S. | Phase 1 | |
Regenerative medicine / cell therapy (Collaboration with RACTHERA Co., Ltd.) |
CT1-DAP001/DSP-1083 (Allogeneic iPS [induced pluripotent stem] cell-derived dopaminergic neural progenitor cells) |
Parkinson’s disease | Japan | Under preparation for the NDA |
U.S. | Phase 1/2 (Investigator-initiated study) |
|||
Phase 1/2 (Company-sponsored clinical study) |
||||
HLCR011 (Allogeneic iPS cell-derived retinal pigment epithelial cells) |
Retinal pigment epithelium tear | Japan | Phase 1/2 | |
DSP-3077 (Allogeneic iPS cell-derived retinal sheet) |
Retinitis pigmentosa | U.S. | Phase 1/2 |
Oncology
Brand name/Generic name/Product code | Proposed indication | Region | Development stage |
---|---|---|---|
enzomenib/DSP-5336 | Acute myeloid leukemia | U.S., Japan | Phase 2 |
nuvisertib/TP-3654 | Myelofibrosis | U.S., Japan | Phase 1/2 |
DSP-0390 | Glioblastoma | U.S., Japan | Phase 1 |
SMP-3124 | Solid tumors | U.S., Japan | Phase 1/2 |
Others
Brand name/Generic name/Product code | Proposed indication | Region | Development stage |
---|---|---|---|
KSP-1007 | Complicated urinary tract infections and Complicated intra-abdominal infections, Hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia | U.S., Japan | Phase 1 |
fH1/DSP-0546LP | Influenza | Europe | Phase 1 |